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Aberrant Skp2 signaling has been implicated as
a driving event in tumorigenesis. Although the under-
lying molecular mechanisms remain elusive, cyto-
plasmic Skp2 correlates with more aggressive forms
of breast and prostate cancers. Here, we report that
Skp2 is acetylated by p300 at K68 and K71, which is
a process that can be antagonized by the SIRT3
deacetylase. Inactivation of SIRT3 leads to elevated
Skp2 acetylation, which leads to increased Skp2
stability through impairment of the Cdh1-mediated
proteolysis pathway. As a result, Skp2 oncogenic
function is increased, whereby cells expressing
an acetylation-mimetic mutant display enhanced
cellular proliferation and tumorigenesis in vivo.More-
over, acetylation of Skp2 in the nuclear localization
signal (NLS) promotes its cytoplasmic retention,
and cytoplasmic Skp2 enhances cellular migration
through ubiquitination and destruction of E-cad-
herin. Thus, our study identifies an acetylation-
dependent regulatory mechanism governing Skp2
oncogenic function and provides insight into how
cytoplasmic Skp2 controls cellular migration.
INTRODUCTION
The F-box protein S-phase kinase associated protein 2 (Skp2)
forms an SCF-type E3 ubiquitin ligase complex by associating
with Cullin-1, Skp1, and Rbx1 (Frescas and Pagano, 2008).
Previous studies have shown that Skp2 plays an important
role in governing cell cycle progression and cell survival by
promoting the destruction of numerous tumor suppressor
proteins, including p27, p21, p57, p130, and FOXO1 (Cardozo
and Pagano, 2004), thereby functioning as a proto-oncogene.Notably, overexpression of Skp2 induces low-grade carci-
nomas in the mouse prostate (Shim et al., 2003) and facilitates
the transformation of Rat1 cells (Gstaiger et al., 2001). More-
over, Skp2 overexpression has been detected in various types
of cancers, including lymphomas (Lim et al., 2002) and prostate
(Yang et al., 2002) and breast carcinomas (Traub et al., 2006),
and it has been associated with poor prognosis as well as
tumor metastasis (Li et al., 2004). In agreement with a critical
role for Skp2 in tumor progression, Skp2/ mice are resistant
to tumor development induced by loss of p53 or PTEN (Lin
et al., 2010). Therefore, a more complete understanding of
how Skp2 activity is regulated would benefit not only basic
cancer research but also clinical diagnosis and, ultimately,
cancer therapy.
We and others have identified APC/Cdh1 as the upstream E3
ligase that promotes Skp2 destruction (Bashir et al., 2004; Wei
et al., 2004). However, loss of Cdh1 is not a frequent event in
human cancers, whereas elevated phosphoinositide 3-kinase
(PI3-K)/Akt signaling is considered a hallmark of more aggres-
sive cancers (Luo et al., 2003). Furthermore, a correlation
between Skp2 overexpression and elevated Akt activity has
been reported in many carcinomas (Mamillapalli et al., 2001).
In agreement with this model, we and others have demonstrated
that Akt1, but not Akt2, phosphorylates Skp2 at Ser72, protect-
ing Skp2 from Cdh1-mediated degradation and localizing a
pool of Skp2 to the cytoplasm by impairing its nuclear localiza-
tion signal (NLS) function (Gao et al., 2009; Lin et al., 2009).
However, Ser72 in human Skp2 is not conserved in mice and
some other species, suggesting the existence of alternative
pathways in the regulation of Skp2 function.
It has been reported that Skp2/ mouse embryonic fibro-
blasts (MEFs) have significantly impaired migratory capacity
compared to their wild-type counterparts (Lin et al., 2009). More-
over, ectopically expressed Skp2 harboring a nuclear export
signal (NES) rescues the migration defect, whereas p27 degra-
dation is unaffected (Lin et al., 2009). These results indicate
that cytoplasmic Skp2 may control cell migration in a mannerCell 150, 179–193, July 6, 2012 ª2012 Elsevier Inc. 179
that is independent of its role in cell-cycle regulation. In support
of this notion, Skp2 cytoplasmic localization has been observed
in many clinical tumor samples and is correlated with aggressive
malignancy and poor prognosis (Drobnjak et al., 2003; Radke
et al., 2005; Signoretti et al., 2002). However, the mechanisms
by which Skp2 controls cell migration and potentially tumor
metastasis remain unclear.
RESULTS
Skp2 Is Acetylated by p300 at Both K68 and K71 within
Its NLS Region
Skp2 was reported to interact with p300 to influence the tumor
suppressor function of p53 (Kitagawa et al., 2008). This promp-
ted us to determine whether Skp2 function is modulated by
p300, whose acetyl transferase activity is activated by Akt-
mediated phosphorylation (Huang and Chen, 2005). In agree-
ment with a previous report (Kitagawa et al., 2008), an interaction
between p300 and Skp2 (Figures 1A and S1A available online) is
readily detected (Figure 1A). Furthermore, acetylation of Skp2 is
detected after ectopic expression of p300, but not other acetyl
transferases, which include CBP and GCN5 (Figure S1B). More-
over, acetylation of endogenous Skp2 is observed after induc-
tion of p300 acetyl transferase activity through activation of
PI3K/Akt (Huang and Chen, 2005) by insulin (Figure 1B). On the
other hand, inhibition of p300 enzymatic activity by Garcinol
(Balasubramanyam et al., 2004) suppressed insulin-induced
Skp2 acetylation (Figure 1C), indicating a critical role for p300
in Skp2 acetylation.
Using deletion constructs, we determined that Skp2 acety-
lation sites are primarily located within the NLS sequence
that contains four lysine residues (Figures 1D, 1E, S1C, and
S1D). We next used mutagenesis to demonstrate that Skp2
acetylation occurs at K68 and K71, which are evolutionarily
conserved (Figures 1F, 1G, and S1E). K68 acetylation was
also confirmed by mass spectrometry (Figure S1F). Moreover,
mouse Skp2 is also acetylated by p300 within the conserved
NLS (Figure 1H).
SIRT3 Specifically Interacts with and Deacetylates Skp2
Recent studies have shown that acetylation of numerous
proteins, such as FOXO3a (Brunet et al., 2004; Motta et al.,
2004), PPARg (Picard et al., 2004), and p53 (Vaziri et al.,
2001), is a dynamic process that can be catalytically reversed
by specific deacetylase(s). Because the Sirtuin family of deace-
tylases has been demonstrated to play critical roles in tumori-
genesis and cellular metabolism (Haigis and Sinclair, 2010),
we tested whether members of the Sirtuin family could
specifically deacetylate Skp2. Among the various Sirtuin family
members examined, only SIRT3 and SIRT4 specifically inter-
acted with Skp2 (Figure 2A). As SIRT3 has been recently char-
acterized as a tumor suppressor protein (Finley et al., 2011a;
Kim et al., 2010) that specifically interacts with Skp2 (Yang
et al., 2011), we further examined a potential role for SIRT3 in
regulation of Skp2 acetylation. We detected a specific interac-
tion between Skp2 and SIRT3 (Figures 2B and S2A). Further-
more, ectopic expression of WT-SIRT3, but not a catalytic-
inactive mutant (H248Y) of SIRT3 (Schwer et al., 2002), led to180 Cell 150, 179–193, July 6, 2012 ª2012 Elsevier Inc.a significant decrease of in vivo Skp2 acetylation (Figure 2C)
detected by an antibody that can recognize acetylation of
Skp2 at K68 and K71 (Figure S1G). Using the anti-Ac-
K68K71-Skp2 antibody, we further showed that recombinant
SIRT3 efficiently deacetylates Skp2 in vitro, a process that is
blocked by nicotinamide (NAM), a pan-Sirtuin family inhibitor
(Figures 2D and 2E). In support of a physiological role for
SIRT3 in Skp2 deacetylation, depletion of SIRT3 (Figures 2F
and 2G), but not SIRT4 (Figures 2I and 2J), led to an increase
in acetylation of endogenous Skp2. Furthermore, inhibition of
reactive oxygen species (ROS) production with N-acetyl-L-
cysteine (NAC) (Finley et al., 2011a) did not cause any notice-
able changes in the elevated acetylation of Skp2 in SIRT3/
cells, arguing that SIRT3 may directly regulate Skp2 acetylation
status instead of through modulating ROS production (Figures
2H and S2B) (Bell et al., 2011; Jing et al., 2011). Finally, deple-
tion of SIRT3 (Figures 2K, S2C, and S2D), but not SIRT4
(Figures S2E–S2G), led to a moderate increase in Skp2 abun-
dance. These results indicate that enhanced acetylation stabi-
lizes Skp2. In support of this notion, we observed an inverse
correlation between Skp2 and SIRT3 immunohistochemical
staining in an array of breast cancer clinical samples (Figures
2L and 2M). This result suggests that loss of SIRT3 may lead
to elevated Skp2 expression in breast cancers. In support of
a tumor suppressor function for SIRT3 (Finley et al., 2011a;
Kim et al., 2010), depletion of SIRT3 facilitates in vivo tumori-
genesis in a xenograft model (Figures 2N and S2M). Further-
more, depletion of endogenous Skp2 severely retarded the
in vivo tumorigenesis of SIRT3/ cells (Figures 2N and S2J–
S2L), but not the transformed WT-MEFs (Figures S2M and
S2N). Together, these results indicate that the Skp2 signaling
pathway may be a major route through which SIRT3 executes
its tumor suppressor function.
Skp2 Protein Is Regulated by p300-Mediated
Acetylation
Our previous studies indicated that a region within Skp2
between residues 46 and 90, which contains the Ser72 Akt phos-
phorylation site as well as the two acetylated lysines K68 and
K71, is both necessary and sufficient for its interaction with
Cdh1 (Bashir et al., 2004; Wei et al., 2004). Moreover, phosphor-
ylation of Skp2 at Ser72 by Akt impairs Cdh1 interaction with
Skp2, leading to its stabilization (Gao et al., 2009; Lin et al.,
2009). Thus, we next examined whether Skp2 acetylation at
K68 and K71 also interferes with Cdh1-mediated Skp2 degra-
dation. Consistent with a previous report (Turnell et al., 2005),
depletion of CBP leads to stabilization of most of the examined
Cdh1 downstream substrates, including Cyclin A, Cyclin B,
Plk1, and Cdc20 (Figure 3A). Notably, depletion of p300 leads
to a significant decrease in Skp2 abundance (Figure S3A), espe-
cially in mid to late G1 (Figure 3A). Interestingly, this phenotype
seems to be unique to Skp2 because p300 depletion did not
cause significant changes in other Cdh1 targets (Turnell et al.,
2005). This result is further supported by a reciprocal set of
experiments in which Skp2 was stabilized by coexpression of
p300 (Figure S3B).
To further understand the role of p300-mediated acetylation
in Skp2 stability, various Skp2 constructs were transfected
- +
IB: Flag-Skp2
IB: HA-p300
IB: Flag-Skp2
IB: Ac-K
HA-p300
Flag-Skp2
IP: Flag
WCL
W
T 90
D
E F
A
HA-p300
Flag-Skp2-N285 K6
8R
K
71
R
K
73
R
N
LS
W
T
IB: Flag-Skp2
IB: HA-p300
IB: Flag-Skp2
IB: Ac-K
IP:Flag
- + - + - + - + - +
G
IP
Ct
rl
IB: Skp2
IB: p300
W
CL
- + - +
IB: Ac-K
IB: Flag
IB: HA
IP: Flag
WCL
- +
W
T N
LSH
Flag-mSkp2Human (63-80)
Chimpanzee (63-80)
Macaque (63-80)
Dog (63-80)
Cow (63-80)
Horse (63-80)
Pig (63-80)
Rat (63-80)
Mouse (63-80)
68 71 73 77
ESPPRKRLKSKGSDKDFV
ESPPRKRLKSKGSDKDFV
ESPPRKRLKSKGSEKDFV
QSPPRKRLKSKGNDKDFV
QSPPRKRLKSKGNDKDFV
QSPPRKRLKSKGNDKDFV
QSPPRKRLKSKGNEKDFV
QSPPRKRLKSKGSDKDFV
QSPPRKRVKGKGSDKDFV
WCL
HA-p300
IB: Flag
Skp2-WT
NLS
Leucine-rich domainF-box
Nuclear Localization Signal (NLS)
90
63-QSPPRKRLKSKGSDKDFV-80
68 71
p3
00
IP: Skp2
WCL
+-Insulin
IB: Ac-K
IB: Ac-K68K71-Skp2
IB: pS72-Skp2
IB:Skp2
IB:Skp2
IB:pS473-Akt
C
B
73
IB: Ac-K
1Insulin (h) 2 20
WCL
IP: Skp2
Garcinol - +- -
77
IB: Skp2
IB: Skp2
Figure 1. Skp2 Is Acetylated by p300 at K68 and K71
(A) Immunoblot (IB) analysis of 293T whole-cell lysates (WCL) and anti-p300 immunoprecipitates (IP). Rabbit IgG was used as a negative control for the
immunoprecipitation procedure.
(B and C) IB analysis of WCL derived from HeLa cells that were serum starved for 24 hr and then collected after 1 hr following addition of insulin to activate the
PI3K/Akt signaling pathway. Cells were pretreated with TSA (2 mM) and NAM (10 mM) for 1 hr before the addition of insulin.
(D) Schematic representation of the Skp2 deletion mutants used in (E) and (F).
(E and F) IB analysis of WCL and anti-Flag IP derived from 293T cells transfected with HA-p300 and various Flag-human Skp2 constructs.
(G) Sequence alignment of the putative acetylation sites K68 and K71 in Skp2 from different species.
(H) IB analysis of WCL and anti-Flag IP derived from 293T cells transfected with HA-p300 and the indicated Flag-mouse Skp2 constructs.
See also Figure S1.
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into HeLa cells, and their expression levels were monitored
during cell-cycle progression. A K/R replacement was used
to generate acetylation-deficient mutants while both K/L
(Rea et al., 2000; Schwer et al., 2002) and K/Q replacements
(Karanam et al., 2007; Kemper et al., 2009) were used to mimic
lysine-acetylation. WT-Skp2 levels are decreased in early- to
mid-G1 phase where APC/Cdh1 is highly active. Similar to
the phosphomimetic mutant (S72D/S75D), acetylation-mimetic
mutants (K68Q, K68L, K71Q, and K71L) are degraded with
significantly slower kinetics than WT-Skp2. Similar to S72A,
K68R and K71R mutants are degraded more rapidly than
WT-Skp2 (Figure 3B). However, it should be noted that the
transcription of transfected Skp2 constructs is driven by
the cytomegalovirus (CMV) promoter, which is different from
the transcription of endogenous Skp2 that can be activated
by E2F1 after cells enter the S phase (Figure 3A) (Zhang and
Wang, 2006). Thus, they cannot faithfully phenocopy endoge-
nous Skp2 expression in the S phase (Figures 3A and 3B).
Using glutathione S-transferase (GST) pull-down analysis, we
showed that replacement of K68 or K71 by acetylation-mimetic
amino acids disrupts the interaction between Skp2 and
Cdh1 (Figure 3C). To eliminate the possible nonspecific effect
derived from amino acid substitution, we performed in vitro
pull-down experiments with biotinylated peptides derived
from the Cdh1-interaction motif of Skp2 (aa 49–88; Figure 3D)
to illustrate that acetylation of K68 or K71 significantly reduced
the interaction between Cdh1 and Skp2 in a synergistic
manner (Figure 3E). Importantly, we further showed that
SIRT3 could catalytically remove the acetylation of K68 and
K71 from the acetylated Skp2 peptides, restoring the interac-
tion between Skp2 and Cdh1 in vitro (Figure 3F). These results
support the notion that p300-mediated acetylation of Skp2
impairs interaction between Skp2 and Cdh1, allowing evasionFigure 2. SIRT3 Interacts with and Deacetylates Skp2
(A) Autoradiography of 35S-labeled Sirtuins bound to HA-Skp2 immunoprecipitate
a negative control.
(B) IB analysis of WCL and anti-Skp2 IP derived from HeLa cells that were infected
for the immunoprecipitation procedure.
(C) IB analysis of WCL and anti-Flag IP derived from 293T cells transfected with
(D) Schematic representation of the various biotinylated peptides used in (E). Wh
(E) 2 mg of indicated peptides were incubated in the presence or absence of reco
were added into the reaction. The indicated amount of peptides after reaction was
Skp2 antibody.
(F) IB analysis of WCL and anti-Skp2 IP derived from HeLa cells that were infec
indicated cells were serum starved for 24 hr and then collected at the indicated tim
for 1 hr before the addition of insulin.
(G–I) IB analysis of WCL and anti-Skp2 IP derived from WT, SIRT3/ (G–H), or S
serum starved for 24 hr and then collected 2 hr following addition of insulin. Cells
indicated, 10 mM ROS inhibitor NAC were added for 16 hr before harvesting for
(J) IB analysis of WCL and anti-Skp2 IP derived from HeLa cells that were infec
indicated cells were serum starved for 24 hr and then collected at the indicated tim
for 1 hr before addition of insulin.
(K) IB analysis of WCL derived from WT or SIRT3/ MEFs.
(L andM) Representative images of SIRT3 and Skp2 expression in breast tumor ce
classified as low, medium, or high based on the intensities of the IHC staining, a
histogram in (M).
(N) Growth curves for the xenograft experiments with the indicated tumor cells tha
were injected. The visible tumors were measured at the indicated days. Error ba
See also Figure S2.of Cdh1-mediated proteolysis pathways and subsequent
Skp2 stabilization.
Acetylation-Dependent Regulation of Skp2 Oncogenic
Functions
Because overexpression of Skp2 has been associated with
tumorigenesis, we next evaluated whether acetylation of Skp2
by p300 also governs Skp2 oncogenic activity. We generated
LNCaP cell lines stably expressing various Skp2 constructs (Fig-
ure 4A). Because both KQ and KL acetylation-mimetic mutants
behave similarly in biochemical and cellular assays (Figures
3B–C and 5B-C), we utilized KL as an acetylation-mimetic and
KR as an acetylation-deficient mutant. As illustrated in Figures
4A and S4A, ectopic expression of both the acetylation-deficient
(K68R/K71R, denoted as KRKR) and acetylation-mimetic (K68L/
K71L, denoted as KLKL) mutants promoted destruction of the
Skp2 substrate p21 as efficiently as wild-type Skp2. Interest-
ingly, the acetylation-mimetic mutant has an enhanced capacity
in promoting the destruction of FOXO1 (Figure 4A). Furthermore,
KLKL-expressing LNCaP cell lines grow more rapidly than other
LNCaP stable cell lines (Figure 4B). However, further studies are
required to determine whether other substrates, in addition to
FOXO1, contribute to this phenotype. Regardless, this pheno-
type could be due to increased cell cycle progression (Fig-
ure S4B), as KLKL-expressing LNCaP cells display elevated
bromodeoxyuridine (BrdU) staining (Figure 4C). In support of
this, depletion of SIRT3, which results in increased acetylation
of Skp2 (Figures 2F and 2G), also leads to increased incorpora-
tion of BrdU (Figures S4C and S4D). Ectopic expression of
Skp2-KLKL mutant also significantly promotes in vivo tumori-
genesis in a xenograft mouse model (Figures 4D and 4E). These
results indicate that acetylation of Skp2 positively regulates its
oncogenic function, partly through modulating its stability.d from the transfected 293T cells. Empty vector (EV) transfection was used as
with the indicated lentiviral vector. Anti-HA IgG was used as a negative control
HA-p300, Flag-Skp2, and the various Flag-SIRT3 constructs.
ere indicated, the K68 and/or K71 residue is acetylated.
mbinant SIRT3 at 37C for 2 hr. Where indicated, 1.5 mM NAD or 20 mM NAM
spotted on nitrocellulose membrane and immunoblotted with the Ac-K68K71-
ted with the indicated lentiviral vector. Before Skp2 immunoprecipitation, the
e periods following the addition of insulin. Cells were pretreated with TSA (2 mM)
IRT4/ (I) MEFs. Before Skp2 immunoprecipitation, the indicated cells were
were pretreated with TSA (2 mM) for 1 hr before the addition of insulin. Where
IP (H).
ted with the indicated lentiviral vector. Before Skp2 immunoprecipitation, the
e periods following the addition of insulin. Cells were pretreated with TSA (2 mM)
lls as assessed by immunohistochemistry (L). Both Skp2 and SIRT3 levels were
nd the percentages of patients classified in each category are depicted in the
t were inoculated subcutaneously. In each flank of nine nudemice, 83 106 cells
rs represent ±SEM, and *p < 0.05 (Student’s t test).
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Figure 3. p300-Dependent Acetylation of Skp2 Impairs Cdh1-Mediated Skp2 Proteolysis Pathway
(A) IB analysis of HeLa cells transfected with the indicated siRNA oligos after synchronization with nocodazole and release at the indicated time periods.
(B) IB analysis of HeLa cells transfected with limited amount of the indicated Flag-Skp2 constructs, along with a green fluorescent protein (GFP) as a transfection
control. HeLa cells were synchronized in the M phase with nocodazole and then released into G1 for the indicated time periods.
(C) Autoradiography of 35S-labeled Cdh1 bound to the indicated GST fusion proteins.
(D) Schematic representation of the various biotinylated peptides used in Figures 3E, 3F, 5D, and 5E, which are derived from the Cdh1-interaction motif of Skp2.
Where indicated, the K68 and/or K71 residue is acetylated.
(E) Autoradiography of 35S-labeled Cdh1 bound to the indicated biotinylated peptides.
(F) Autoradiography of 35S-labeled Cdh1 bound to the indicated biotinylated peptides that have been subject to SIRT3 in vitro deacetylation assays as described
in Figure 2E.
See also Figure S3.
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Figure 4. Acetylation of Skp2 Positively Regulates Skp2 Oncogenic Functions
(A) IB analysis of LNCaP cell lines stably transfected with the indicated HA-Skp2 constructs.
(B) Cell growth curves of the various LNCaP cell lines stably expressing the indicated HA-Skp2 constructs. Results were presented as mean ±SD from three
independent experiments.
(C) Various LNCaP cell lines stably expressing the indicated HA-Skp2 constructs were pulsed with BrdU for 30 min, and the BrdU incorporation rate was
measured. Results were presented as mean ±SD from three independent experiments.
(D and E) LNCaP cells stably transfected with the indicated HA-Skp2 constructs (with empty vector as a negative control) were injected subcutaneously into nude
mice (n = 5 for each group) and examined over time for in vivo tumorigenesis. Pictures in (E) were taken 6 weeks after injection. Results were presented as mean
±SD and *p < 0.05 (Student’s t test).
See also Figure S4.p300 Promotes Skp2 Translocation into the Cytoplasm
Because acetylation of lysines within an NLS often influences
cellular localization (di Bari et al., 2006; Dietschy et al., 2009),
we hypothesized that acetylation of the Skp2 NLS (Figure 5A)
may influence its localization. Indeed, cytoplasmic relocalization
was observed when wild-type Skp2 was cotransfected with
p300 (Figure S5A). Importantly, the same phenotype was
observed with S72A-Skp2, implying that p300-mediated acety-
lation governs Skp2 cellular localization independent of Akt-
mediated Skp2 phosphorylation (Figure S5A).
We next evaluated the contribution of acetylation of individual
lysine residues for Skp2 cytoplasmic localization. Interestingly,
the K71R mutant behaves similar to WT-Skp2, primarily local-izing to the nucleus, whereas the acetylation-mimetic K71Q,
K71L K68L, K68Q, K68L/K71L, and K68Q/K71Q mutants are
largely retained in the cytoplasm (Figure 5B). Curiously, the acet-
ylation-deficient K68R or K68R/K71R mutants also localize
mainly in the cytoplasm (Figure 5B). This might be due to the
fact that the first lysine residue of a given NLS is critical for its
recognition by the importin complex, and even replacement of
this first lysine abolishes NLS function (Fabbro and Henderson,
2003; Poon and Jans, 2005). Consistent with this notion, both
K68R and K68R/K71R mutants display decreased interaction
with the importin a5/7 subunit (Figures 5C and S5B). On the
other hand, substitution of the second lysine (K71R) does not
affect its recognition by the importin a5/7 subunit (Figures 5CCell 150, 179–193, July 6, 2012 ª2012 Elsevier Inc. 185
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Figure 5. Acetylation of Skp2 by p300 Promotes Skp2 Cytoplasmic Localization
(A) Sequence alignment of the Skp2 NLS with p21, p27, and FOXO1 NLS.
(B) Immunofluorescence and DAPI staining of 293T cells transfected with the indicated Flag-Skp2 constructs.
(C) IB analysis of WCL and anti-Flag IP derived from 293T cells transfected with the indicated Flag-Skp2 constructs.
(D) Autoradiography of 35S-labeled importin a1 or importin a5 bound to the indicated biotinylated peptides.
(E) Autoradiography of 35S-labeled importin a5 or importin a7 bound to the indicated biotinylated peptides, which have been subject to SIRT3 in vitro deace-
tylation assays as described in Figure 2E.
See also Figure S5.and S5B). Most importantly, all acetylation-mimetic mutants do
not interact with the importin complex (Figures 5C and S5B).
To provide a better understanding of how acetylation of Skp2
affects its recognition by the importin complex, we performed
pull-down assays with biotinylated peptides that contain the
canonical NLS (Figure 3D). Importin a5, but not a1 (Figure 5D),186 Cell 150, 179–193, July 6, 2012 ª2012 Elsevier Inc.interacts with Skp2 in vitro. Moreover, acetylation of K71 leads
to a significant decrease, whereas acetylation of K68 results in
an almost complete loss of recognition by importin a5 in vitro
(Figure 5D). Furthermore, SIRT3 efficiently attenuates acetyla-
tion of Skp2 at K68 and K71, which leads to a complete restora-
tion of importin a5 and a7 interactions with Skp2 in vitro
(Figure 5E). These results indicate that acetylation of the first
lysine (K68) and, to a lesser extent, the second lysine (K71),
within the NLS disrupts its recognition by the importin complex,
offering amolecular mechanism for acetylation-dependent regu-
lation of Skp2 cytoplasmic localization.
Importantly, consistent with previous reports (Bao et al., 2010;
Cooper and Spelbrink, 2008; Hirschey et al., 2010; Jing et al.,
2011; Schwer et al., 2002), we found that SIRT3 exclusively
localized in the mitochondria (Figures S5D and S5E). Moreover,
WT-Skp2 mainly localized in the nucleus (Figures S5C and S5F),
whereas the acetylation-mimetic KLKL-Skp2 is primarily local-
ized in the cytoplasm (Figures S5C and S5G). Interestingly,
inactivating SIRT3 with the pan-Sirtuin inhibitor, NAM, led to
increasedmitochondrial localization of Skp2 (Figure S5D). More-
over, there is a significant enrichment of mitochondrial locali-
zation for the acetylation-mimetic Skp2 mutant, KLKL-Skp2
(Figures S5C and S5G). These results indicate that the acety-
lated form of Skp2 might specifically interact with SIRT3 in the
mitochondria where the deacetylation of Skp2 may occur. In
keeping with this notion, purified mitochondria from WT, but
not SIRT3/, MEFs could deacetylate Skp2 in vitro (Figures
S5H and S5I).
Skp2 Plays an Important Role in Regulating Cell
Migration
In agreement with a previous report (Lin et al., 2009), Skp2/
MEFs exhibit decreased ability to close a wounded area in
monolayer cultures (Figures 6A and 6B) as well as to migrate
toward chemoattractants in Transwell assays (Figure 6C). Re-
expression of Skp2 inSkp2/MEFs rescued these deficiencies,
demonstrating that Skp2 can directly modulate cell migration
(Figure 6C). Moreover, expression of the KLKL acetylation-
mimetic Skp2 mutant in Skp2/ MEFs further enhances migra-
tion when compared to cells expressing wild-type-Skp2 or
the acetylation-deficient KRKR-Skp2 (Figure 6C). Similarly,
LNCaP cells expressing KLKL-Skp2 also display increased cell
migration compared to wild-type Skp2 (Figures S6A–S6D). Inter-
estingly, we detected an increased expression of E-cadherin in
Skp2/ MEFs (Figure 6D), as well as in Skp2-depleted normal
human fibroblasts (Figure 6E). More importantly, a marked
increase of E-cadherin expression is observed after depletion
of endogenous Skp2 in various epithelial carcinoma cell lines,
including SKOV3 (Figure 6F), DU145 (Figure S6H), and HeLa
cells (Figure S6I). In support of a role of E-cadherin in Skp2-medi-
ated migration, an inverse correlation was observed between
cell migration ability (Figure 6C) and E-cadherin expression
levels in Skp2/ MEFs reconstituted with either wild-type,
KLKL-Skp2, or KRKR-Skp2 (Figure 6G). In keeping with these
results, ectopic expression ofWT- or KLKL-Skp2 in various other
epithelial carcinoma cell lines, including DU145 (Figure 6H),
MCF7 (Figures S6E and S6L), T47D (Figure S6F), and ZR75 (Fig-
ure S6G), led to a severe reduction of E-cadherin abundance.
Conversely, depletion of endogenous SIRT3 in MCF7 (Figure 6I),
ZR75 (Figure 6J), and DU145 (Figure S6J) resulted in a dramatic
elevation of Skp2 expression and a subsequent reduction of
E-cadherin abundance. Altogether, these results support the
notion that the SIRT3/Skp2 signaling pathway is a major physio-
logical regulator that controls the stability of the E-cadherintumor suppressor. Importantly, E-cadherin mRNA levels are
not increased in Skp2/ MEFs (Figure S6K), indicating that
Skp2 regulates E-cadherin abundance primarily through post-
translational modifications. Consistent with this, a physiological
interaction between endogenous Skp2 and E-cadherin (Fig-
ure 6K) is detected. Furthermore, ectopically expressed Skp2
promotes E-cadherin degradation, which can be rescued with
the proteasome inhibitor MG132 (Figure 6L). Additionally,
MG132 treatment in multiple cell lines led to a marked increase
in endogenous E-cadherin (Figures 6M, 6N, and S6M). These
results suggest the involvement of the 26S proteasome pathway
in regulating E-cadherin abundance. We also observed an
inverse correlation between the Skp2 and E-cadherin expression
in breast cancer clinical samples (Figures 6O and 6P). Thus,
these data altogether suggest that the SIRT3/Skp2 signaling
axis may promote cellular migration in part by promoting E-cad-
herin destruction.
Skp2 Promotes the Ubiquitination and Destruction
of E-Cadherin in a CKI-Dependent Manner
We next explored the mechanism by which Skp2 promotes
E-cadherin destruction. E-cadherin is phosphorylated by Casein
Kinase I (CKI) (Dupre-Crochet et al., 2007), and this negatively
regulates E-cadherin function. Consistent with this, Skp2
expression promotes E-cadherin degradation in a CKI-depen-
dent manner (Figure 6L), which is in agreement with the well-
established mechanism whereby Skp2 requires prior phosphor-
ylation of its targets for destruction (Frescas and Pagano, 2008).
Moreover, mutation of Ser846, Ser849, Ser852, and Ser855 (4A)
in the serine-rich region of E-cadherin significantly attenuates
phosphorylation by CKI in vitro (Figures 7A and 7B). However,
residual phosphorylation of E-cadherin remains even in the 4A
mutant, suggesting the existence of additional potential CKI
sites (Figure 7B). A closer examination of the mouse E-cadherin
sequence reveals that Ser840 and Ser842 are possible CKI
consensus motifs (Figure 7A). In support of this, additional
mutation of Ser840 and Ser842 (6XA mutant) leads to a further
decrease in CKI-mediated E-cadherin phosphorylation in vitro
(Figure 7B). Also, E-cadherin phosphorylation by CKI promotes
its interaction with Skp2 (Figure 7C), but this is significantly
impaired in the 6A mutant, both in vitro (Figure 7D) and in cells
(Figure 7E). Mutation of the CKI sites also abolishes Skp2-medi-
ated E-cadherin degradation (Figures 7F and S7A) and impairs
the ability of Skp2 to promote E-cadherin ubiquitination in a
CKI-dependent manner (Figure 7G). Consistent with a tumor
suppressor role for E-cadherin, ectopic expression of the nonde-
gradable version (6XA) of E-cadherin in LNCaP cells (Figure S7B)
resulted in a significant reduction in cellular migration ability (Fig-
ure S7C), which correlates with a significant decrease in their
ability to form tumors in vivo (Figures S7D–S7G). These results
indicate that misregulation of the SIRT3/Skp2 signaling pathway
might result in aberrant expression of the E-cadherin tumor
suppressor, thus facilitating tumorigenesis.
DISCUSSION
Deregulation of the Skp2/p27 pathway, including overexpres-
sion of Skp2 or loss of p27, is frequently observed in numerousCell 150, 179–193, July 6, 2012 ª2012 Elsevier Inc. 187
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Figure 6. Cytosolic Skp2 Plays a Critical Role in Cellular Migration
(A and B) Skp2 is required for cell migration. WT and Skp2/ MEFs were plated for in vitro wound healing assays (A). Results in (A) were quantified in (B) and
presented as mean ±SD from three independent experiments.
(C) WT and Skp2/ MEFs were infected with the indicated viral constructs before plating for transwell assay. The results were quantified and presented as
mean ±SD from three independent experiments.
(D) IB analysis of WT and Skp2/ MEFs, synchronized by serum starvation for 72 hr and then released by readdition of serum for the indicated periods.
(E and F) IB analysis of normal human fibroblasts (E) or SKOV3 epithelial cancer cell line (F) infected with the indicated lentiviral shRNA vectors.
(G) IB analysis of WT and Skp2/ MEFs infected with the indicated viral constructs.
(H) IB analysis of DU145 cells infected with the indicated viral constructs.
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human tumors, but the underlying molecular mechanisms
remain largely undescribed. Although phosphorylation-medi-
ated regulatory mechanisms control the activity of multiple
F-box proteins, including Skp2 (Gao et al., 2009; Lin et al.,
2009) and Fbx4 (Barbash et al., 2008), regulation by acetylation
has not been previously linked to F-box control. Our results
demonstrate that p300-mediated acetylation of Skp2 affects
its stability and cytoplasmic localization, which, in turn, can influ-
ence its oncogenic activity (Figure 7H). These results suggest
that acetylation-mediated posttranslational modifications might
also control the function of other F-box proteins.
Skp2 has been reported to interact with p300 and to nega-
tively affect the ability of p300 to modulate apoptosis induced
by p53 (Kitagawa et al., 2008). Our data provide an additional
mechanism for the Skp2/p300 interaction, whereby p300 can
reciprocally govern Skp2 function in an acetylation-dependent
manner. Our studies also point to a potential crosstalk between
the Akt and p300 pathways in the regulation of Skp2. In this
regard, Akt activates p300 acetyl-transferase activity (Huang
and Chen, 2005) to influence Skp2 acetylation (Figures 1B
and 1C). Therefore, in humans and other mammals in which
Ser72 is conserved, Akt could potentially regulate Skp2 func-
tion by two related mechanisms, one through direct Ser72
phosphorylation and the other through activation of p300 to
promote Skp2 acetylation (Figure S7H). However, in mice,
Skp2 Ser72 is replaced with a Gly; therefore, additional studies
are required to examine whether Akt indirectly affects Skp2
function through a p300-dependent manner (Figure S7I). As
the crosstalk between histone phosphorylation and acetylation
is well established (Cheung et al., 2000; Lo et al., 2000), we
evaluated whether Akt phosphorylation of Skp2 affects acetyla-
tion at K68 and K71. Acetylation-mimetic mutants displayed
a moderate decrease in Ser72 phosphorylation, indicating that
Skp2 acetylation at K68 or K71 might negatively affect Ser72
phosphorylation (Figure S1I). However, phosphorylation of
either Ser72 or Ser75 does not affect the ability of p300 to
acetylate Skp2 (Figure S1J). Because both Akt-mediated phos-
phorylation of Ser72 and p300-mediated acetylation at K68
and K71 serve to promote Skp2 cytoplasmic localization as
well as to stabilize Skp2, activation of either pathway promotes
Skp2 oncogenic signaling. It is possible that p300 and Akt are
activated in response to distinct upstream signals to modulate
Skp2 in specific settings.
In addition to Skp2, many of Skp2 downstream substrates,
including p21 (Zhou et al., 2001), p27 (Liang et al., 2002; Shin
et al., 2002; Viglietto et al., 2002), and FOXO1 (Brunet et al.,
1999), have been characterized as Akt phosphorylation targets.
Interestingly, Akt-mediated phosphorylation all resulted in a(I and J) IB analysis of MCF7 (I) or ZR75 epithelial cancer cell line (J) infected wit
(K) IB analysis of MCF7 WCL and anti-E-cadherin IP. Anti-HA IgG was used as a
(L) IB analysis of WCL of HeLa cells transfected with the indicated plasmids. Ce
overnight before harvesting.
(M and N) IB analysis of WCL derived from DU145 (M) or SKOV3 (N) cells treated
(O and P) Representative images of E-cadherin and Skp2 expression in breast tum
levels were classified as low,medium, or high based on the intensities of the IHC st
in the histogram in (P).
See also Figure S6.relocation of these proteins to the cytosol (Figure S5S). Espe-
cially for FOXO1, Akt-mediated phosphorylation of FOXO1
at Ser256 is required for subsequent ubiquitination by Skp2
(Huang et al., 2005), suggesting that Akt drives both FOXO1
and Skp2 to the cytosol where phosphorylated FOXO1 is
actively degraded by SCFSkp2 (Zhang, 2010). Similar to Skp2,
FOXO1 is actively acetylated by p300 (Figure S5Q) at multiple
lysine residues within its NLS (Matsuzaki et al., 2005; Perrot
and Rechler, 2005). Furthermore, p27, but not p21, could be
acetylated by p300 (Figures S5J and S5K). Interestingly, to
mimic acetylation, replacement of K153 to Q within the NLS of
p27 led to a significant increase in the cytoplasmic localization
of p27 (Figure S5L) that correlates with reduced interaction
with the importin complex subunits (Figures S5M–S5O). These
results suggest that both Akt-mediated phosphorylation and
p300-mediated acetylation could cooperatively regulate the
cellular localization of Skp2 as well as its various downstream
ubiquitin substrates. However, further studies are warranted to
better understand the biological significance of this complicated
regulation of the Skp2 signaling pathway.
More importantly, we also identified SIRT3 as an Skp2 deace-
tylase. SIRT3 has been recently shown to function as a tumor
suppressor by regulating both genomic stability and tumor cell
metabolism (Bell et al., 2011; Finley et al., 2011a; Kim et al.,
2010). Moreover, SIRT3 deletion increases cell proliferation,
although the underlyingmolecular mechanisms remain unknown
(Bell et al., 2011; Finley et al., 2011a; Kim et al., 2010). Interest-
ingly, we detected an inverse correlation between Skp2 and
SIRT3 levels in breast cancer clinical samples (Figures 2L and
2M), which suggests that reduced SIRT3 expression may have
a causal effect on Skp2 overexpression in breast and other
cancers.
Interestingly, our results suggest that acetylation of Skp2
might differentially regulate the destruction of its downstream
targets, such as p21 and FOXO1 (Figure 4A). As dimerization
has been recently characterized as a key regulatory mechanism
for the function of several F-box proteins (Barbash et al., 2008;
Tang et al., 2007b; Welcker and Clurman, 2007), and as p300-
mediated acetylation has been reported to influence protein
dimerization (Tang et al., 2007a; Yuan et al., 2005), we further
explored whether acetylation of Skp2 affects dimerization. We
found that p300-mediated Skp2 acetylation promotes Skp2
dimerization, and this is impaired upon deletion of the NLS
(Figure S5U). Mutation of either K68 or K71 disrupts the ability
of Skp2 to dimerize, whereas an acetylation-mimetic mutant
(KLKL) forms dimers even in the absence of p300 (Figures
S5V–S5Y). Our results therefore suggest that dimerization might
affect the Skp2 substrate spectrum.h the indicated lentiviral shRNA vectors.
negative control for the immunoprecipitation procedure.
lls were treated 20 hr posttransfection with the proteasome inhibitor MG132
with 10 mM MG132 for 12 hr before harvesting.
or cells as assessed by immunohistochemistry (O). Both Skp2 and E-cadherin
aining, and the percentages of patients classified in each category are depicted
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Figure 7. Skp2 Promotes the Ubiquitination and Destruction of E-Cadherin in a CKI-Dependent Manner
(A) Sequence alignment of the putative CKI phosphorylation sites in Skp2 from various species.
(B) Indicated GST-fusion proteins were incubated with CKId and [g-32P]ATP. The kinase reaction products were resolved by SDS-PAGE, and phosphorylation
was detected by autoradiography.
(C and D) Autoradiography of 35S-labeled Skp2 bound to the indicated GST-fusion proteins. Where indicated, GST-fusion proteins were pretreated with CKId
before pull-down assays were performed.
(E) IB analysis of WCL and anti-Myc IP derived from HeLa cells transfected with the indicated Myc-E-cadherin constructs.
(F) IB analysis of WCL from HeLa cells transfected with the indicated plasmids.
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Skp2 cytoplasmic staining correlated with metastasis and
high-grade breast and prostate cancers (Dowen et al., 2003;
Drobnjak et al., 2003; Radke et al., 2005; Signoretti et al.,
2002), though the underlying molecular mechanisms are
not known. Here, we found that Skp2 promotes E-cadherin
degradation in a CKI-dependent manner (Figure 7), which is
consistent with the established role of E-cadherin as a critical
cell adhesion protein whereby E-cadherin loss promotes cell
migration (Giehl and Menke, 2008; Schmalhofer et al., 2009).
Although promoter methylation or loss of the E-cadherin genetic
locus can account for reduced E-cadherin expression, it has
also been reported that the E-cadherin is an unstable protein
such that enhanced proteolysis contributes to decreased
E-cadherin levels (Yang et al., 2006). Furthermore, we detected
an inverse correlation between Skp2 and E-cadherin expression
in an array of breast cancer clinical samples (Figures 6O and 6P).
These results suggest that the effects of Skp2 on cellular
migration could be partly mediated by modulation of E-cadherin
stability.
Skp2/ mice are resistant to tumorigenesis that is induced
by overexpression of the BCR-Abl oncoprotein (Agarwal et al.,
2008) or by loss of the tumor suppressors p53 or PTEN (Lin
et al., 2010). Consistent with this, inhibition of Skp2 in MCF7
breast cancer cells suppresses cell-cycle progression (Sun
et al., 2007). These results support the idea of Skp2-targeted
therapy, given the central role of the Skp2/p27 pathway in breast
cancer initiation and metastasis. However, the critical role of
Skp2 inmalignancy has not yet been fully elucidated. Our studies
provide a mechanism whereby acetylation of Skp2 by p300
regulates protein stability and cellular localization, thus modu-
lating oncogenic signaling, and our studies also provide further
rationale for the development of Skp2 antagonists for cancer
therapy.
EXPERIMENTAL PROCEDURES
Transwell Cell Migration Assay and In Vitro Wound Healing Assay
Cell migration and wound healing assays were performed as described previ-
ously (Lin et al., 2009).
Skp2 Binding Assays
Binding to immobilized GST proteins and biotinylated peptides was performed
as described previously (Wei et al., 2004; Wei et al., 2005).
In Vitro Deacetylation Assay
Recombinant human SIRT3 protein was purchased from BIOMOL. To perform
the in vitro deacetylation assay, 2 mg of acetylated Skp2 peptides were incu-
bated with recombinant SIRT3 in 30 ml of SDAC buffer (50 mM Tris-HCl
[pH 9.0], 1 mM MgCl2, 50 mM NaCl, and 0.5 mM dithiothreitol [DTT]), with or
without 1.5 mM nicotinamide adenine dinucleotide (NAD) at 37C for 2 hr.
Where indicated, 20 mM nicotinamide (NAM) were added. The reactions
were spotted on nitrocellulose membrane to detect deacetylation of Skp2
peptides with anti-Ac-K68K71-Skp2 antibody. The rest of the reactions were
subjected to subsequent in vitro peptide-protein binding assays.(G) SCFSkp2 E3 ligase complex promotes E-cadherin ubiquitination in vitro.Where
ubiquitination assays.
(H) Proposed model for how acetylation of Skp2, which subsequently regulates
governed by both p300 and SIRT3.
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